Member Login
Market Reports
 |
|
This situation is expected to change dramatically over the next decade as the emergence of minimally invasive and transcatheter heart valve repair techniques significantly reduces the risks and costs associated with heart
valve procedures. Collapsible and compressible valve prostheses, transcatheter valve repair technologies,
anticalcification treatments, and innovative valve suturing technologies are among the key developments that
will enable this trend, and their impact is expected to be felt as soon as 2005, contributing to the 6.4% annual
growth in heart valves and related products, from $420 million in 2001 to $573 million in 2006. This initial
expansion will be followed by dramatic gains in the ensuing four-year period ending in 2010 as the transcatheter
segment alone primarily repair products used to treat congestive heart failure potentially exceeds $500 million.
Tissue-engineered heart valves are expected to become a clinical reality only after 2006; however, their impact,
too, will be significant. In the interim, tissue valve prostheses will continue to gain share from mechanical
prostheses, and improved products and protocols for valve repair, including minimally invasive surgical repair
performed without cardiopulmonary bypass, will increase their share of the total procedure caseload. EXECUTIVE SUMMARY I. Overview of Heart Valve Disease II. Procedure Trends III. Product Markets IV. Surgical Valve Products V. Transcatheter Valve Products VI. Companies 1.1 Valve Types and Function 1.2 Role of Valves in Cardiac Cycle 1.3 Epidemiology of Heart Valve Disease 1.3.1 Rheumatic Heart Disease 1.3.2 Acquired Valve Disorders 1.3.3 Congenital Heart Defects 1.3.4 Bacterial Endocarditis 1.4 Diagnosis of Heart Valve Disease 1.4.1 Ausculation 1.4.2 Electrocardiography 1.4.3 Chest X-Rays 1.4.4 Echocardiography 1.4.5 Coronary Angiography 1.5 Treatment of Heart Valve Disease 1.5.1 Medical Management 1.5.2 Surgical Intervention 1.5.3 Transcatheter Valve Repair and Replacement 2.1 Replacement Procedure 2.1.1 Traditional Median Sternotomy Approach 2.1.2 Minimally Invasive Approaches 2.1.2.1 Procedure 2.1.2.2 Advantages 2.1.2.3 Limitations 2.1.2.4 Preliminary Outcomes 2.1.2.5 Enabling Technologies 2.1.2.6 Conclusions 2.2 Valve Prostheses 2.2.1 Major Heart Valve Types 2.2.1.1 Mechanical Valves 2.2.1.2 Xenograft Tissue Valves 2.2.1.3 Allograft Valves 2.2.2 Configurations 2.2.2.1 Mechanical Valve Designs 2.2.2.2 Tissue Valve Sources and Designs 2.2.2.2.1 Porcine versus Bovine 2.2.2.2.2 Stented versus Stentless 2.3 Prosthetic Heart Valve Products 2.3.1 Mechanical Heart Valves 2.3.1.1 Competitive Analysis 2.3.2 Tissue Heart Valves 2.3.2.1 Competitive Analysis 2.3.3 Allograft Valves 2.3.3.1 Competitive Analysis 2.3.3.2 Suppliers 2.3.4 Emerging Prosthesis Technologies 2.3.4.1 Autograft Valves 2.3.4.1.1 Competitive Analysis 2.3.4.2 Tissue-Engineered Valves 2.3.4.2.1 Competitive Analysis 2.3.4.2.2 Conclusions 2.3.4.3 Tri-Leaflet Mechanical Heart Valves 2.3.4.3.1 Competitive Analysis 2.3.4.4 Collapsible Tissue Valves 2.3.4.4.1 Competitive Analysis 2.3.5 Valve Suturing Technologies 2.3.5.1 Competitive Analysis 2.4 Surgical Valve Replacement Procedures 2.5 Market Analysis 2.5.1 Mechanical Valves 2.5.2 Xenograft Tissue Valves 2.5.3 Allograft Valves 3.1 Techniques 3.2 Operative Approaches 3.2.1 Traditional Open Heart Surgery 3.2.2 Direct Vision Minimal Access Heart Valve Repair 3.2.3 Video-Assisted Endoscopic Valve Repair 3.2.4 Beating Heart Valve Repair 3.3 Annuloplasty Rings 3.3.1 Designs 3.3.2 Products 3.3.2.1 Competitive Analysis 3.4 Procedure Forecast 3.5 Market Analysis 4.1 Clinical Applications 4.1.1 Rastelli Procedure 4.1.2 Ross Procedure 4.1.3 Thoracic Aortic Aneurysm with Valve Involvement 4.1.4 Aortic Endocarditis 4.2 Products and Suppliers 4.2.1 Competitive Analysis 4.3 Procedure Forecast 4.4 Market Analysis 5.1 Percutaneous Balloon Valvuloplasty 5.1.1 Clinical Applications 5.1.2 Procedure 5.1.3 Double Balloon versus Inoue Technique 5.1.4 Clinical Outcomes 5.1.5 Products 5.1.5.1 Competitive Analysis 5.1.6 Procedures 5.1.7 Market Analysis 5.2 Percutaneous Valve Repair and Replacement 5.2.1 Rationale 5.2.2 Approaches 5.2.2.1 Percutaneous Annuloplasty 5.2.2.2 Percutaneous Valve Repair 5.2.2.3 Percutaneous Valve Replacement 5.2.3 Products and Suppliers 5.2.3.1 Competitive Analysis 5.2.4 Procedure Trends 5.2.5 Market Forecast 6.1 Advanced Tissue Sciences 6.2 AorTech International plc 6.3 ATS Medical 6.4 Autogenics 6.5 Axya Medical 6.6 Boston Scientific Corporation/Scimed 6.7 CardioMend 6.8 Corazon Technologies 6.9 Cryolife 6.10 Edwards Lifesciences 6.11 Evalve 6.12 3F Therapeutics 6.13 Genzyme Biosurgery 6.14 JOMED NV 6.15 Jostra 6.16 Medical Carbon Research Institute 6.17 Medtronic 6.18 MitraLife 6.19 Percutaneous Valve Technologies 6.20 St. Jude Medical 6.21 Sorin Biomedica 6.22 Sulzer Medica (Sulzer Carbomedics) 6.23 Tepha 6.24 Toray Group 6.25 Triflo Medical
* Single License allows for report sharing within one company location.
Hundreds of thousands of patients in the U.S., including a large share with congestive heart failure, could potentially benefit from heart valve repair or replacement. However, because both are currently performed as
open heart procedures requiring cardiopulmonary bypass, less than 94,000 individuals underwent heart valve
surgery in 2001 due to its invasiveness, risks, and cost.
SECTION 1: OVERVIEW OF HEART VALVE DISEASE
SECTION 2: SURGICAL VALVE REPLACEMENT
SECTION 3: SURGICAL VALVE REPAIR
SECTION 4: SPECIALTY VALVE PRODUCTS
SECTION 5: TRANSCATHETER VALVE TECHNOLOGIES
SECTION 6: COMPANY PROFILES
Company listing available upon request.
** Corporate License allows for report sharing within all company locations.
This report is listed in the following markets:
Cardiovascular